46.60
price down icon8.56%   -4.36
pre-market  시장 영업 전:  46.80   0.20   +0.43%
loading
전일 마감가:
$50.96
열려 있는:
$50.73
하루 거래량:
2.88M
Relative Volume:
3.99
시가총액:
$3.33B
수익:
$900.66M
순이익/손실:
$-453.20M
주가수익비율:
-7.8451
EPS:
-5.94
순현금흐름:
$-274.19M
1주 성능:
-17.19%
1개월 성능:
-15.67%
6개월 성능:
+29.26%
1년 성능:
+62.99%
1일 변동 폭
Value
$46.37
$51.43
1주일 범위
Value
$45.40
$56.20
52주 변동 폭
Value
$24.00
$58.38

PTC 테라퓨틱스 Stock (PTCT) Company Profile

Name
명칭
Ptc Therapeutics Inc
Name
전화
(908) 222-7000
Name
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Name
직원
0
Name
트위터
@PTCBio
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
PTCT's Discussions on Twitter

PTCT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PTCT
Ptc Therapeutics Inc
46.60 3.33B 900.66M -453.20M -274.19M -5.94
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-11 업그레이드 BofA Securities Underperform → Neutral
2025-03-07 개시 Scotiabank Sector Perform
2024-12-13 업그레이드 Morgan Stanley Equal-Weight → Overweight
2024-12-03 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2024-10-10 재개 Raymond James Mkt Perform
2024-09-04 개시 Robert W. Baird Outperform
2024-08-26 재개 UBS Buy
2024-05-20 업그레이드 Raymond James Underperform → Mkt Perform
2023-12-19 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2023-12-08 개시 Wells Fargo Overweight
2023-10-30 업그레이드 Oppenheimer Perform → Outperform
2023-10-27 다운그레이드 Citigroup Neutral → Sell
2023-10-06 다운그레이드 Truist Buy → Hold
2023-09-18 다운그레이드 Citigroup Buy → Neutral
2023-09-15 다운그레이드 Raymond James Outperform → Underperform
2023-03-17 개시 SVB Securities Market Perform
2022-12-14 개시 Goldman Sell
2022-09-12 개시 Jefferies Buy
2022-09-09 개시 Morgan Stanley Equal-Weight
2022-09-01 개시 Citigroup Buy
2022-04-04 재개 Cantor Fitzgerald Overweight
2021-10-18 다운그레이드 BofA Securities Neutral → Underperform
2021-04-26 재개 Credit Suisse Neutral
2021-03-29 업그레이드 RBC Capital Mkts Underperform → Sector Perform
2021-02-12 다운그레이드 BofA Securities Buy → Neutral
2021-01-05 업그레이드 Citigroup Neutral → Buy
2020-11-30 다운그레이드 RBC Capital Mkts Sector Perform → Underperform
2020-10-30 다운그레이드 Citigroup Buy → Neutral
2020-10-28 개시 UBS Neutral
2020-10-07 업그레이드 JP Morgan Neutral → Overweight
2020-08-25 개시 Raymond James Outperform
2020-04-09 업그레이드 Citigroup Neutral → Buy
2020-02-20 다운그레이드 Citigroup Buy → Neutral
2020-02-20 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2019-11-12 개시 SunTrust Buy
2019-05-13 업그레이드 BofA/Merrill Neutral → Buy
2019-04-11 개시 Bernstein Outperform
2018-10-03 업그레이드 BofA/Merrill Underperform → Neutral
2018-10-01 개시 Cantor Fitzgerald Overweight
2018-07-19 개시 Credit Suisse Outperform
2018-06-18 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2018-04-04 다운그레이드 Barclays Equal Weight → Underweight
2018-01-29 재개 RBC Capital Mkts Sector Perform
2017-11-16 업그레이드 JP Morgan Underweight → Neutral
2017-10-26 다운그레이드 BofA/Merrill Neutral → Underperform
2017-10-09 다운그레이드 JP Morgan Neutral → Underweight
모두보기

PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스

pulisher
04:58 AM

(PTCT) Technical Data - news.stocktradersdaily.com

04:58 AM
pulisher
Apr 01, 2025

PTC Therapeutics (NASDAQ:PTCT) Trading Down 8.8% Following Analyst Downgrade - MarketBeat

Apr 01, 2025
pulisher
Apr 01, 2025

JPMorgan Chase & Co. Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $75.00 - MarketBeat

Apr 01, 2025
pulisher
Apr 01, 2025

Pictet Asset Management Holding SA Has $33.24 Million Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Raymond James Financial Inc. Makes New $2.20 Million Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Mar 31, 2025
pulisher
Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025
pulisher
Mar 30, 2025

Natixis Advisors LLC Invests $544,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Mar 30, 2025
pulisher
Mar 30, 2025

PTC Therapeutics says Duchenne drug Translarna is no longer authorized in EU - MSN

Mar 30, 2025
pulisher
Mar 29, 2025

Cibc World Markets Corp Acquires Shares of 7,127 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Mar 29, 2025
pulisher
Mar 28, 2025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider.com

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics Faces EU Setback on Translarna - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics says EC will not renew market authorization for muscle disorder drug - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics stock slips as EU ends Translarna nod (PTCT) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics faces EC setback on Translarna in Europe - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics (PTCT) Faces EU Setback for DMD Drug Translarna - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics says EC not to renew market authorization for muscle disorder drug - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe - Quantisnow

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics Loses EU Authorization for Translarna in Duchenne Muscular Dystrophy - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics: European Commission Decides To Adopt CHMP Negative Opinion On Translarna - Nasdaq

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics says European Commission will remove muscle disorder drug - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics Provides Regulatory Update On Translarna(TM) (Ataluren) In Europe - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

PTC Therapeutics faces EC setback on Translarna in Europe By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 26, 2025

Sector Gamma AS Purchases Shares of 65,250 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Mar 26, 2025
pulisher
Mar 25, 2025

A Shareholder alert for PTC Therapeutics, Inc was sent by Bronstein, Gewirtz and Grossman, LLC to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 25, 2025
pulisher
Mar 25, 2025

AlphaQuest LLC Has $49,000 Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Mar 25, 2025
pulisher
Mar 24, 2025

PTC Therapeutics (NASDAQ:PTCT) Sets New 52-Week HighShould You Buy? - MarketBeat

Mar 24, 2025
pulisher
Mar 24, 2025

First Week of May 16th Options Trading For PTC Therapeutics - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Leigh Syndrome Treatment Market Size in 7MM is expected to grow - openPR

Mar 24, 2025
pulisher
Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Sells 15,278 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Mar 24, 2025
pulisher
Mar 23, 2025

Proficio Capital Partners LLC Takes $758,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Mar 23, 2025
pulisher
Mar 22, 2025

Stephanie Okey Sells 5,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat

Mar 22, 2025
pulisher
Mar 21, 2025

Insider Sell Alert: Eric Pauwels Sells Shares of PTC Therapeutics Inc (PTCT) - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Charles Schwab Investment Management Inc. Trims Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Mar 21, 2025
pulisher
Mar 20, 2025

PTC Therapeutics reports progress in PKU treatment study By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

PTC Therapeutics reports progress in PKU treatment study - Investing.com India

Mar 20, 2025
pulisher
Mar 19, 2025

PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 19, 2025
pulisher
Mar 19, 2025

JPMorgan Chase & Co. Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $78.00 - MarketBeat

Mar 19, 2025
pulisher
Mar 19, 2025

PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month High After Analyst Upgrade - MarketBeat

Mar 19, 2025
pulisher
Mar 18, 2025

PTC Therapeutics chief business officer sells $630,104 in stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

PTC Therapeutics chief business officer sells $630,104 in stock By Investing.com - Investing.com UK

Mar 18, 2025
pulisher
Mar 18, 2025

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Mar 18, 2025
pulisher
Mar 17, 2025

Mark Elliott Boulding Sells 15,521 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat

Mar 17, 2025
pulisher
Mar 17, 2025

Director Okey Stephanie sold $270,000 worth of shares (5,000 units at $54.00), decreasing direct ownership by 36% to 8,867 units (SEC Form 4) - Quantisnow

Mar 17, 2025
pulisher
Mar 17, 2025

PTCT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 17, 2025

PTC 테라퓨틱스 (PTCT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
자본화:     |  볼륨(24시간):